Home › Companies › DRTS

Alpha Tau Medical

Market cap $1.12B 92.5M shares (vendor count, Nov 18, 2026) × $12.09 close Nov 17, 2026 · share count from the market-data vendor, not the SEC cover page

Most recent annual filing: 2025-12-31

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. Head & Neck Cancer +2026Head & Neck Cancer +, 2026, routine
  2. IMPACT pancreas pilot corporate updateLate 2026 / early 2027IMPACT pancreas pilot corporate update, Late 2026 / early 2027, routine
  3. Alpha DaRT SCC pivotal toplineEarly 2027Alpha DaRT SCC pivotal topline, Early 2027, thesis-defining
  4. Pancreas IMPACT corporate updateearly 2027Pancreas IMPACT corporate update, early 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

Technology platforms

Alpha DaRT

Alpha Diffusing Alpha-emitters Radiation Therapy — intratumoral Radium-224-embedded radioactive source technology delivering controlled release of alpha-emitting atoms throughout solid tumors; focus areas include squamous cell carcinoma, glioblastoma multiforme, pancreatic cancer, head and neck cancer, and other solid tumors

Capital (as filed)

Cash
$12.2M cash and cash equivalents · Dec 31, 2025 (20-F)
Short-term investments
$60.9M Dec 31, 2025
Operating cash flow
−$6.7M annual ÷ 4, year to Dec 31, 2025 (20-F)
As stated in coverage
$105M cash per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (19)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (18 calls)

Every verdict Biotech Distilled has published on Alpha Tau Medical, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Alpha Tau Medical (DRTS): Scientific Deep Dive of Alpha DaRT Strong proof-of-concept in skin SCC with internal organ pipeline as a free call option, but prudent to hold a small position until the H2 2026 ReSTART binary readout.
  2. Speculative buy speculative UPDATE: Alpha Tau Medical (DRTS) – Pancreatic Data Hits the "Safety" Bullseye; FDA Submission Adds Regulatory Momentum Pancreatic safety data removes a major tail risk and FDA PMA module submission confirms commercial execution, improving the risk/reward profile.
  3. Speculative buy speculative UPDATE: Alpha Tau (DRTS) Doubles Down on the U.S. Five concurrent U.S. trials demonstrate supply chain resilience and the data waterfall starts in H2 2026, with firm catalyst timelines now in place.
  4. Speculative buy speculative UPDATE: Alpha Tau (DRTS) – The Japan Catalyst Hits Japan Shonin approval is the first commercial authorization outside Israel, significantly de-risking the regulatory pathway and shrinking the risk discount.
  5. Speculative buy speculative UPDATE: Alpha Tau (DRTS) - FY25 Financials $76.9M cash provides a two-year runway through the H2 2026 ReSTART binary readout, removing the dilution overhang risk.
  6. Speculative buy speculative UPDATE: Alpha Tau Medical (DRTS) — The Pancreas Franchise Goes Global, IMPACT Slips a Quarter Pancreas franchise is compounding across two continents with both SOC backbones covered; the Q2→Q3 IMPACT slip is acceptable for a 33% larger trial, and the ReSTART binary is unaffected.
  7. Speculative buy speculative UPDATE: Alpha Tau Medical (DRTS) — The $300M Shelf Lands, ASCO Caps the Pancreas Run The $300M shelf and live ATM are prudent pre-positioning for a commercial ramp, not panic; the ASCO acceptance and unchanged ReSTART binary keep the thesis intact despite the 7.7% dilution-driven dip.
  8. Speculative buy speculative UPDATE: Alpha Tau Medical (DRTS) — 100% Local Disease Control at the DDW Podium 100% local disease control in 19 evaluable pancreatic cancer patients at DDW validates the proof-of-physics translation from skin to internal organs, strengthening the secondary thesis.
  9. Speculative buy speculative UPDATE: Alpha Tau Medical (DRTS) — ReSTART Enrollment Done, GBM Safety Call Set, Italy Opens ReSTART enrollment completion mechanically locks the H2 2026 binary readout, while GBM safety call and Italy pancreas opening continue to compound the platform thesis.
  10. Speculative buy speculative UPDATE: Alpha Tau Medical (DRTS) — The Unforgiving Organ Talks Back, And It Says Yes 100% local disease control and 67% CR in the first three GBM patients with clean safety de-risks the brain leg of the platform, though n=3 caveat remains and ReSTART is still the binary.
  11. Speculative buy speculative UPDATE: Alpha Tau Medical (DRTS) — The Pancreas OS Number Lands, And It's Better Than the Benchmarks n=58 pooled pancreas OS data beats historical benchmarks across 2L and 3L lines with a manageable safety profile, anchoring the IMPACT pivotal hypothesis.
  12. Speculative buy speculative UPDATE: Alpha Tau Medical (DRTS) — Tolmar Takes Prostate, And It Pays a Premium Tolmar's exclusive U.S. prostate commercialization deal with $35M committed cash, a 25% equity premium, and a $161.5M milestone ladder validates the platform and co-funds the manufacturing bear case.
  13. Speculative buy speculative UPDATE: Alpha Tau Medical (DRTS) — FDA Greenlights REGAIN Expansion, Two New Sites Join FDA clearance to expand REGAIN to remaining 7 patients across three academic centers validates the safety throttle and operationally unlocks the GBM leg of the platform.
  14. Speculative buy speculative UPDATE: Alpha Tau Medical (DRTS) — The Abscopal Bet Cashes a Ticket 100% systemic ORR and 18.2-month mOS with Keytruda in elderly HNSCC validates the abscopal combination thesis, opening a materially larger commercial framing beyond local ablation.
  15. Speculative buy speculative UPDATE: Alpha Tau Medical (DRTS) — The Share Count Answer, And a $68.8M Loss That Isn't H1 financials show only 4.3M new shares issued (mostly strategic), $104.8M cash, and a $68.8M headline loss that is 61% non-cash warrant accounting, making the financing picture more comfortable than modeled.
  16. Speculative buy speculative UPDATE: Alpha Tau Medical (DRTS) — IMPACT Closes at 48 Patients, Four Times the Original Design IMPACT enrollment completed at 48 patients across 10 centers ahead of schedule, with management naming a planned pivotal study for the first time and data guided to early 2027.
  17. Speculative buy speculative UPDATE: Alpha Tau Medical (DRTS) — REGAIN Doubles, and "Market Submission" Enters the GBM Vocabulary FDA-approved IDE supplement doubles REGAIN to 20 patients with new endpoints, and management's 'market submission' language signals the feasibility study could become a filing pathway.
  18. Speculative buy speculative UPDATE: Alpha Tau Medical (DRTS) - Six for Six, With Asterisks SNO data shows only 3 confirmed CRs vs. the 6-of-6 headline, with 2 open necrosis-vs-progression calls and ReSTART slipping to early 2027, but local control remains intact and the thesis is not broken.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (4 quotes from 4 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (31)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. No press release captured yet; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

4 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)